Mundipharma picks up a PhIII-ready chemo creation in $250M deal
A small, virtual German biotech called CellAct Pharma has struck a licensing deal for their sole clinical-stage cancer therapy. The partners are staying mum about the details, but it includes a package of milestones and a “double-digit” upfront that total $250 million.
The Dortmund, Germany-based CellAct turned up at ASCO last summer with collective Phase I and II data on 39 patients, which they say demonstrated an ability to rein in tumor growth among patients with drug-resistant biliary tract cancer. The therapy, CAP7.1, is a prodrug which converts into the chemotherapy etoposide in target tissues, possibly offering an alternative approach to treating end-stage disease from solid tumors.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.
